Pfizer Inc. $PFE Shares Sold by Canal Insurance CO

Canal Insurance CO reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 20.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 400,000 shares of the biopharmaceutical company’s stock after selling 100,000 shares during the period. Pfizer comprises about 2.2% of Canal Insurance CO’s holdings, making the stock its 16th largest holding. Canal Insurance CO’s holdings in Pfizer were worth $10,192,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Curio Wealth LLC increased its stake in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the last quarter. Harbor Asset Planning Inc. purchased a new position in shares of Pfizer in the 2nd quarter valued at $29,000. Howard Hughes Medical Institute purchased a new position in shares of Pfizer in the 2nd quarter valued at $30,000. True Wealth Design LLC raised its stake in Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 974 shares in the last quarter. Finally, Darwin Wealth Management LLC purchased a new stake in Pfizer in the second quarter valued at $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: New oncology data showed a Pfizer cancer combination produced stronger tumor shrinkage versus standard treatment in advanced colorectal cancer — supportive for commercial/label expansion prospects in a high‑value oncology indication. Pfizer cancer combo shows strong tumor shrinkage in colorectal cancer trial
• Positive Sentiment: Pfizer advanced a lung‑cancer combo into a global Phase 2/3 program and launched a head‑to‑head colorectal cancer Phase 3 for PF‑08634404 — progress that de‑risks late‑stage oncology pipeline timing and future revenue potential. Pfizer advances new lung cancer combo in global Phase 2/3 trial
• Positive Sentiment: Positive data on Pfizer’s Braftovi regimen were reported, reinforcing the company’s targeted‑therapy franchise and near‑term oncology catalysts. Positive new data on Pfizer’s Braftovi regimen
• Positive Sentiment: CEO Albert Bourla signaled ambition to build an obesity consumer market comparable to Viagra’s consumer expansion; that, plus the $10B Metsera acquisition, positions Pfizer to capture a potentially large, recurring market if regulatory/launch execution succeeds. Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra
• Positive Sentiment: BMO reiterated a Buy and $30 price target, highlighting oncology, obesity pipeline upside and post‑LOE recovery prospects as key upside drivers. Pfizer: Underappreciated Growth Story
• Neutral Sentiment: Zacks’ preview of Q4 suggests oncology revenue will see steady growth from Seagen ADCs and key brands but be partially offset by pricing and competitive pressures — a mixed operational outlook ahead of earnings. Inside Pfizer’s Oncology Performance Ahead of Q4 Results
• Neutral Sentiment: Broker actions are mixed: UBS flagged the Metsera deal favorably but kept a Neutral stance ($25 PT), and the street average rating is around Hold — indicating uncertainty on near‑term revenue trajectory. UBS Likes Pfizer’s MTSR Obesity Deal but Stays Neutral on PFE Pfizer Receives Average “Hold” Rating
• Neutral Sentiment: Pfizer’s JPMorgan presentation material was published (slides/transcript) — useful for detail on strategy and pipeline but not an immediate stock mover absent new guidance. Pfizer Presents at J.P. Morgan Healthcare Conference
• Negative Sentiment: Pfizer stopped a mid‑stage lupus skin trial, removing a smaller autoimmune opportunity and signaling a pipeline setback that may reduce near‑term upside from non‑oncology indications. Pfizer Ends Mid-Stage Lupus Skin Trial
• Negative Sentiment: Analysts and commentators continue to flag legacy risks — a looming patent cliff, rising debt and earnings pressure post‑LOE — which cap valuation upside until clearer revenue recovery paths materialize. Pfizer’s Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research analyst reports. Scotiabank assumed coverage on Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price on the stock. Wolfe Research set a $24.00 price objective on Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Morgan Stanley cut their target price on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a research report on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus price target of $27.88.

Pfizer Stock Performance

NYSE:PFE opened at $25.12 on Wednesday. The firm’s fifty day moving average price is $25.29 and its 200 day moving average price is $24.97. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The firm has a market cap of $142.83 billion, a price-to-earnings ratio of 14.60 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is currently 100.00%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.